Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of sepranolone in pediatric and adult Tourette syndrome
2021-001045-12Phase 2Completed
- Sponsor
- Asarina Pharma AB
- Start
- Mar 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sepranolone in Tourette syndrome (TS), sponsored by Asarina Pharma AB. Primary endpoint: Change from baseline YGTSS total score. Started Mar 2021; status: completed.
02
Drugs
sepranolone
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on 2021-001045-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001045-12.